Sugi Predict

Sugi Predict / Compounds / SCHEMBL886934

SCHEMBL886934

SCHEMBL886934

CC(Cc1nc(N)c2[nH]cnc2n1)OCP(=O)(O)O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.40
▸ GDA Q9Y2T3 1/20 0.40
▸ CDK1 P06493 9/20 0.39
▸ CCNB1 P14635 9/20 0.39
▸ CCNA2 P20248 9/20 0.39
▸ CDK2 P24941 9/20 0.39
▸ CCNA1 P78396 9/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MGMT P16455 3/20 0.37
▸ HPRT1 P00492 2/20 0.36
▸ KDR P35968 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ TYMP P19971 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16037330 1.00 PDPK1 (0.40) PDPK1GDACDK1CCNB1CCNA2
Hypophosphorous Acid SCHEMBL3803586 0.96 PDPK1 (0.37) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL28890128 0.86 CDK1 (0.39) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL8332940 0.85 CDK1 (0.40) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL8400854 0.85 FGFR1 (0.40) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL30575052 0.85 FGFR1 (0.40) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL16585590 0.85 ANPEP (0.34) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL2824954 0.81 CYP3A4 (0.42) CYP3A4HPRT1TYMP
SCHEMBL28492789 0.81 CYP3A4 (0.42) CYP3A4HPRT1TYMP
SCHEMBL4241363 0.81 PDPK1 (0.42) PDPK1GDACDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682109-B2 Antiviral resistance mutants and applications thereof ABL SA (LU) 2017-06-20 — — US claimed
US-5763424-A SEQUESTERING AGENT GILEAD SCIENCES, INC. (US) 1998-06-09 — — US claimed
WO-2025128741-A1 OCTADECANOID COMPOSITIONS AND METHODS OF ACTIVATING MUCOSAL REPAIR PATHWAYS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-19 — — WO disclosed
US-20240009214-A1 Method of Treating Viral Infection CIPLA LIMITED (IN) 2024-01-11 — — US disclosed
EP-3600332-B1 HIV POST-EXPOSURE PROPHYLAXIS US HEALTH (US) 2023-12-13 — — EP disclosed
US-20220296619-A1 PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE GILEAD SCIENCES, INC. 2022-09-22 — — US disclosed
US-11191763-B2 HIV post-exposure prophylaxis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-12-07 — — US disclosed
US-20200113919-A1 Pharmaceutical Compositions CIPLA LIMITED (IN) 2020-04-16 — — US disclosed
US-20200101072-A1 HIV POST-EXPOSURE PROPHYLAXIS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2020-04-02 — — US disclosed
US-10195222-B2 Acyclic nucleoside phosphonate diesters THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-02-05 — — US disclosed
WO-2019021319-A1 PHARMACEUTICAL COMPOSITIONS CIPLA LIMITED (IN) 2019-01-31 — — WO disclosed
EP-1692278-A1 HBV VARIANTS DETECTION AND APPLICATION Melbourne Health (AU) 2006-08-23 — — EP disclosed
US-20060051743-A1 Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development EVIVAR MEDICAL PTY LTD. (AU) 2006-03-09 — — US disclosed
WO-2005042733-A1 HBV VARIANTS DETECTION AND APPLICATION MELBOURNE HEALTH (AU) 2005-05-12 — — WO disclosed
EP-1499712-A1 HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF Melbourne Health (AU) 2005-01-26 — — EP disclosed
WO-2003087351-A1 HEPATITIS B VIRAL VARIANTS WITH REDUSED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF MELBOURNE HEALTH (AU) 2003-10-23 — — WO disclosed
US-5935946-A TENOFOVIR DISOPROXIL FUMARATE; ANTIVIRAL THERAPY GILEAD SCIENCES, INC. (US) 1999-08-10 — — US disclosed
US-5922695-A COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS GILEAD SCIENCES, INC. (US) 1999-07-13 — — US disclosed
US-5763424-A SEQUESTERING AGENT GILEAD SCIENCES, INC. (US) 1998-06-09 — — US disclosed
US-5733788-A PURIFICATION, LIQUID CHROMATOGRAPHY GILEAD SCIENCES, INC. (US) 1998-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240009214-A1 Method of Treating Viral Infection ACE2, ACE, MTAP PDPK1 1636/4885GDA 706/4885CDK1 1234/4885
US-20200113919-A1 Pharmaceutical Compositions PYGL, PYGM, PTEN PDPK1 401/4885GDA 2641/4885CDK1 1932/4885
US-20220296619-A1 PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE LPXN, TYMP, PARN PDPK1 1638/4885GDA 238/4885CDK1 4057/4885
US-10195222-B2 Acyclic nucleoside phosphonate diesters NTPCR, PNP, TYMP PDPK1 368/4885GDA 68/4885CDK1 948/4885
US-20060051743-A1 Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development DNTT, HAVCR2, RNPEP PDPK1 4285/4885GDA 172/4885CDK1 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.